Aralez Pharmaceuticals Inc. (ARLZ) Stock Rating Reaffirmed by Chardan Capital
Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)‘s stock had its “buy” rating restated by equities researchers at Chardan Capital in a report released on Wednesday. They currently have a $10.00 price target on the stock. Chardan Capital’s price target would indicate a potential upside of 102.02% from the stock’s current price.
Separately, Guggenheim reaffirmed a “buy” rating and issued a $12.00 price target on shares of Aralez Pharmaceuticals in a research report on Monday, August 15th.
Aralez Pharmaceuticals (NASDAQ:ARLZ) traded down 3.32% during midday trading on Wednesday, hitting $4.95. The company had a trading volume of 457,471 shares. Aralez Pharmaceuticals has a 12 month low of $3.10 and a 12 month high of $8.59. The company’s market cap is $322.94 million. The firm has a 50-day moving average price of $5.29 and a 200-day moving average price of $4.20.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/aralez-pharmaceuticals-inc-arlz-stock-rating-reaffirmed-by-chardan-capital-2.html
Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.08. The company earned $12.60 million during the quarter, compared to analyst estimates of $9.70 million. Aralez Pharmaceuticals had a negative net margin of 224.35% and a negative return on equity of 73.21%. The firm’s quarterly revenue was up 142.3% on a year-over-year basis. Equities analysts anticipate that Aralez Pharmaceuticals will post ($1.06) EPS for the current year.
In other news, Director Robert Paul Harris sold 150,000 shares of the stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $5.82, for a total value of $873,000.00. Following the transaction, the director now owns 669,094 shares in the company, valued at approximately $3,894,127.08. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.77% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ARLZ. Bank of Montreal Can acquired a new position in Aralez Pharmaceuticals during the second quarter worth approximately $100,000. Advisor Group Inc. acquired a new position in Aralez Pharmaceuticals during the second quarter worth approximately $118,000. Knott David M acquired a new position in Aralez Pharmaceuticals during the second quarter worth approximately $124,000. Alpine Partners VI LLC acquired a new position in Aralez Pharmaceuticals during the second quarter worth approximately $133,000. Finally, LMR Partners LLP acquired a new position in Aralez Pharmaceuticals during the second quarter worth approximately $145,000. Institutional investors and hedge funds own 49.63% of the company’s stock.
Aralez Pharmaceuticals Company Profile
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.